Atrial Fibrillation Complicated by Heart Failure Induces Distinct Remodeling of Calcium Cycling Proteins

Patrick Lugenbiel, Fabian Wenz, Katharina Govorov, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas*
Department of Cardiology, Medical University Hospital, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany
*dierk.thomas@med.uni-heidelberg.de

Abstract

Atrial fibrillation (AF) and heart failure (HF) are two of the most common cardiovascular diseases. They often coexist and account for significant morbidity and mortality. Alterations in cellular Ca²⁺ homeostasis play a critical role in AF initiation and maintenance. This study was designed to specifically elucidate AF-associated remodeling of atrial Ca²⁺ cycling in the presence of mild HF. AF was induced in domestic pigs by atrial burst pacing. The animals underwent electrophysiologic and echocardiographic examinations. Ca²⁺ handling proteins were analyzed in right atrial tissue obtained from pigs with AF (day 7; n = 5) and compared to sinus rhythm (SR) controls (n = 5). During AF, animals exhibited reduction of left ventricular ejection fraction (from 73% to 58%) and prolonged atrial refractory periods. AF and HF were associated with suppression of protein kinase A (PKA)RII (-62%) and Ca²⁺-calmodulin-dependent kinase II (CaMKII)δ by 37%, without changes in CaMKIIδ autophosphorylation. We further detected downregulation of L-type calcium channel (LTCC) subunit α₂ (-75%), sarcoplasmic reticulum Ca²⁺-ATPase (Serca) 2a (-29%), phosphorylated phospholamban (Ser16, -92%; Thr17, -70%), and phospho-ryanodine receptor 2 (RyR2) (Ser2808, -62%). Na⁺-Ca²⁺ exchanger (NCX) levels were upregulated (+473%), whereas expression of Ser2814-phosphorylated RyR2 and LTCCα₁c subunits was not significantly altered. In conclusion, AF produced distinct arrhythmogenic remodeling of Ca²⁺ handling in the presence of tachycardia-induced mild HF that is different from AF without structural alterations. The changes may provide a starting point for personalized approaches to AF treatment.

Introduction

Effective and safe management of atrial fibrillation (AF) constitutes a major clinical challenge. In particular, the co-existence of heart failure (HF), a common clinical scenario, is associated with increased morbidity and mortality, more rapid disease progression, and reduced efficacy of pharmacologic or interventional treatment of the arrhythmia [1–3]. Progressive electrical atrial remodeling of ion currents and calcium handling supports initiation and perpetuation of
the rhythm disorder. The analysis of underlying mechanisms provides options for target-specific therapy that is required to improve outcome of AF patients [4–6]. However, mechanism-based approaches to AF therapy in cases with concomitant HF are currently limited by an insufficient understanding of molecular remodelling in HF-associated AF. Abnormalities in calcium cycling associated with either AF or HF have been studied previously. In AF, reduced L-type calcium channel (LTCC) current [7] may explain action potential shortening that was observed among chronic (but not paroxysmal) AF patients [8,9]. In addition, increased Ca\(^{2+}\)-calmodulin-dependent kinase II (CaMKII) activity via autophosphorylation, ryanodine receptor type 2 (RyR2) hyperphosphorylation at Ser2808 and Ser2814, and Na+-Ca\(^{2+}\) exchanger 1 (NCX1) upregulation were implicated in delayed afterdepolarizations in chronic AF [8]. When analyzed in the absence of AF, atrial remodeling in canine HF is characterized by increased action potential duration (APD), decreased LTCC current, and enhanced NCX [10,11].

Ca\(^{2+}\)-handling alterations that promote AF in HF subjects are poorly understood despite the high prevalence of AF in HF. Initial data obtained from dogs point towards a molecular interaction of AF and HF in phenotypic expression of critical components of cellular Ca\(^{2+}\) cycling that differs from the sum of effects observed in AF and HF alone, respectively [11]. The aim of the present study was to delineate specific molecular determinants of Ca\(^{2+}\) remodeling in AF and coexisting mild HF. An established porcine model of atrial tachypacing-induced AF complicated by HF [12–16] was employed to elucidate expression and phosphorylation status of Ca\(^{2+}\)-cycling proteins in right atrial tissue samples.

**Materials and Methods**

**Atrial fibrillation / heart failure animal model**

AF was induced by rapid atrial burst pacing in sex-matched domestic swine (<6 months of age; body weight 25 to 30 kg). Animals were sedated with ketamine (100 mg/kg; Roche, Grenzach-Wyhlen, Germany) and midazolam (15 mg/kg, i.m.; Roche), and anesthetized with disopivane (1 ml 1% solution; Astra Zaneca, Wedel, Germany) and isoflurane (1–2%; Baxter, Unterschleißheim, Germany). A pacing lead (4024 CapSure SP, Medtronic, Minneapolis, MN, USA) was inserted under fluoroscopic guidance through the right external jugular vein, fixed in the right atrial appendage, and connected to a pacemaker unit (Medtronic Kappa; Medtronic) placed in a subcutaneous pocket in the right neck. The pacemaker was programmed to apply burst pacing for the entire follow-up period at a frequency of 42 Hz for 2 seconds followed by 2 second intervals where the animals revealed their endogenous heart rate and rhythm. Under equivalent conditions pigs usually develop AF within 1–7 days [12–14,16]. During the 7 day observation period, daily 6-lead ECG recordings were performed to verify AF and to average ventricular response rates that were similar during pacing compared to non-paced intervals. ECG measurements were done while feeding in awake and alert animals. In addition, cardiac tissue samples were obtained from healthy domestic swine during sinus rhythm (SR) with similar weight and age that were not subjected to functional evaluation. This study has been carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health (NIH publication No. 86–23, revised 1985) and with EU Directive 2010/63/EU, and the current version of the German Law on the Protection of Animals was followed. The study has been approved by the Regierungspräsidium Karlsruhe (Karlsruhe, Germany; approval number G-106/10).

**Electrophysiological study**

Electrophysiological (EP) examination was performed in AF animals during SR before pacemaker implantation and after electrical cardioversion before euthanization. Bipolar catheters
were placed in the right atrium via the jugular vein. The EP Lab system (Bard Electrophysiology Division, Lowell, MA, USA) was used to record atrial effective refractory periods (AERP) and corrected sinus node recovery times (SNRT). To determine AERP, repeated trains of 10 stimuli at a fixed cycle length of 500 ms or 400 ms were applied, followed by a single programmed premature stimulus. The coupling interval between the last basic stimulus and the premature stimulus was decreased in 10 ms-steps until no atrial response was recorded. To assess corrected SNRT stimuli with fixed cycle lengths (500 ms and 400 ms) were applied for 30 seconds. The corrected SNRT was calculated by subtracting the intrinsic cycle length from the recorded recovery time.

Echocardiographic examination

Measurements were carried out on the day of pacemaker implantation and at the end of the study (Philips Healthcare Sonos 5500, Hamburg, Germany) during SR following electrical cardioversion. Left ventricular ejection fraction (LVEF) was determined from M-mode measurements as described [14,17].

Western blot analysis

Protein immunodetection was performed by sodium dodecyl sulfate (SDS) gel electrophoresis and Western blotting. The right atrial appendage was dissected, rapidly frozen in liquid nitrogen and stored at -80°C. Samples were homogenized (Yellow line D1 18 basic homogenizer, IKA, Essex, UK), followed by cell lysis in buffer containing 20 mM Tris–HCl, 0.5% NP-40, 0.5% sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, and inhibitors of proteases (Complete) and phosphatases (PhosStop) (Roche Applied Science, Indianapolis, IN, USA). For preparation of sarcoplasmic reticulum fractions atrial tissues were homogenized on ice in a solution containing 0.3 M sucrose, 10 mM imidazole, 30 mM histidine, protease and phosphatase inhibitor (Mini Complete, PhosStop; Roche Applied Science, Indianapolis, IN, USA). Homogenates were centrifuged at 4°C for 20 min at 8000g. The supernatants were collected and centrifuged at 45,000g for 90 min. The pellets were resuspended in a solution containing 0.3 M sucrose, 10 mM imidazole, 30 mM histidine and 0.6 M KCl, and centrifuged at 2000g to remove myofibrillar proteins. Finally, the supernatant was centrifuged at 45,000g for 90 min, and resulting pellets were resuspended in the solution described above.

The protein concentration was determined using the bicinchoninic acid (BCA) protein assay (Thermo Scientific, Rockford, IL, USA). Equal amounts of protein were separated on 6–20% SDS polyacrylamide gels, transferred to polyvinylidene difluoride membranes, and developed using primary antibodies directed against L-type calcium channel (LTCC) α1c subunit (sc-25686; Santa Cruz Biotechnology, Heidelberg, Germany), LTCC α2 subunit (ab62814; Abcam), Na+–Ca2+ exchanger (NCX) 1 (ab2869; Abcam), catalytic protein kinase A (PKA) subunits Ca/β (ab26322; Abcam), phosphorylated regulatory PKA subunit RIIα (Ser99) (ab32390; Abcam), phospholamban (PLN) (MA3-922; Thermo Scientific, Dreieich, Germany), phosphorylated PLN (Ser16) (07-052; Upstate (Merck Millipore), Billerica, MA, USA), phosphorylated PLN (Thr17) (sc-17024-R; Santa Cruz Biotechnology, Heidelberg, Germany), Ca2+-calmodulin-dependent protein kinase II (CaMKII) δ (C1035-04E; Biomol, Hamburg, Germany), autophosphorylated CaMKIIδ (Thr286) (V1111; Promega, Madison, WI, USA), ryanodine receptor type 2 (RyR2) (ab2868; Abcam), phosphorylated RyR2 (Ser2808) (A010-30; Badrilla, Leeds, UK), phosphorylated RyR2 (Ser2814) (A010-31AP; Badrilla), and sarcoplasmic reticulum Ca2+-ATPase (Serca) 2a (sc-8095; Santa Cruz Biotechnology). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit (ab6721; Abcam), mouse anti-goat (sc-2354; Santa Cruz...
Biotechnology), and goat anti-mouse (sc-2005; Santa Cruz Biotechnology) secondary antibodies were used where appropriate.

Signals were developed using the enhanced chemiluminescence assay (ECL Western Blotting Reagents, GE Healthcare, Buckinghamshire, UK) and quantified with ImageJ 1.41 Software (National Institutes of Health, Bethesda, MD, USA). After removal of primary and secondary antibodies, the membranes were reprobed with anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (G8140-11; US Biological, Swampscott, MA, USA) and corresponding secondary antibodies (sc-2005; Santa Cruz Biotechnology). Protein content was normalized to GAPDH for quantification of optical density.

Statistics
Data are expressed as mean ± SEM of n experiments. We used paired and unpaired Student’s t tests (two-tailed tests) to compare the statistical significance of the results. P < 0.05 was considered statistically significant.

Results
Atrial tachypacing-induced AF is associated with rapid ventricular response and impaired left ventricular function

Atrial tachypacing successfully induced AF in all animals following pacemaker implantation (Fig. 1A). AF was characterized by rapid ventricular response rates during follow-up (mean heart rate, 249 ± 49 beats per minute (bpm); n = 5; Fig. 1B). Electrophysiological examinations were performed prior to pacemaker implantation and at the end of the 7 day period to
determine AERP. We observed AERP prolongation at cycle lengths of 500 ms (baseline, AERP$_{500} = 174 \pm 26$ ms; day 7, 263 $\pm$ 45 ms; n = 5; $P = 0.007$; Fig. 1C) and 400 ms (baseline, AERP$_{400} = 166 \pm 33$ ms; day 7, 228 $\pm$ 46 ms; n = 5; $P = 0.040$; Fig. 1D). Corrected SNRT under baseline conditions and at the end of the study were not significantly different at 500 ms basic cycle length (BCL) (49 ms $\pm$ 40 ms at baseline versus 66 ms $\pm$ 22 ms on day 7; n = 5; $P = 0.41$) and at 400 ms BCL (80 ms $\pm$ 49 ms at baseline versus 133 ms $\pm$ 53 ms on day 7; n = 5; $P = 0.19$), respectively (Fig. 1E and F).

Uncontrolled tachycardia during AF resulted in impairment of left ventricular ejection fraction (LVEF). Echocardiograms performed at the beginning of the study during sinus rhythm revealed normal function (LVEF = 73 $\pm$ 6%; n = 5). In contrast, LVEF was significantly reduced to 58 $\pm$ 8% (n = 5; $P = 0.033$) at sacrifice (day 7; Fig. 1G). Furthermore, the mean LA diameter increased from 34 $\pm$ 7 mm prior to initiation of the burst pacing program to 44 $\pm$ 7 mm after 7 days (n = 5; $P = 0.013$; Fig. 1H).

Alterations of protein kinase expression during AF and HF
To delineate remodeling of Ca$^{2+}$-handling during AF in the presence of mild HF, Western blot analyses were performed in five pigs subjected to atrial tachypacing for 7 days. Pigs exhibiting SR that were not subjected to AF induction served as controls (n = 5). We first assessed alterations of key upstream kinases that are responsible for functional regulation of Ca$^{2+}$ cycling proteins through reversible phosphorylation, PKA and CaMKII$\delta$. The reference protein, GAPDH, did not exhibit AF-associated remodeling (Fig. 2A) in accordance with previous studies [18]. AF was associated with 37% decrease of CaMKII$\delta$ expression compared to SR controls ($P = 0.08$; Fig. 2B). There was no significant change of CaMKII$\delta$ autophosphorylation (i.e. persistent activation) at Thr286 in AF animals ($P = 0.47$; Fig. 2C). Relative levels of autophosphorylated / total CaMKII$\delta$ remained unchanged as well (Fig. 2D). Downregulation of PKA-phosphorylated regulatory PKA RII$\alpha$ subunits (at Ser99) by 62% ($P = 0.017$) indirectly reflected reduced activity of the catalytic PKA chain during AF. Total catalytic PKA C$\alpha$/C$\beta$ levels were similar between AF and SR animals ($P = 0.35$) (Fig. 2E and F).

Remodeling of Ca$^{2+}$-handling protein expression and phosphorylation in AF / HF pigs
To further assess alterations of Ca$^{2+}$-signaling during AF complicated by functional LV impairment, we investigated expression of L-type calcium channel $\alpha$ subunits. LTCC $\alpha_2$ subunit levels were significantly lower in AF animals compared to SR (~75%; n = 5; $P = 0.047$), whereas the $\alpha_1c$ subunit was not affected by atrial burst pacing-induced AF and HF (n = 5; $P = 0.71$) (Fig. 3A and B). In contrast to LTCC downregulation, NCX1 expression was increased in animals with AF (+473%; n = 5; $P < 0.0001$; Fig. 3C). In addition to LTCC and NCX1 located in the cell membrane, the intracellular Ca$^{2+}$ content is regulated by the Ca$^{2+}$ pump Serca2a in the sarcoplasmic reticulum membrane and its endogenous inhibitor, PLN. After 7 days of AF with rapid response rate, total PLN levels showed a tendency towards downregulation that was not statistically significant compared to SR animals (n = 5; $P = 0.09$; Fig. 4A). Phosphorylation of PLN by CaMKII at Thr17 (~70%; n = 5; $P = 0.014$) and by PKA at Ser16 (~92%; n = 5; $P = 0.003$) was significantly reduced (Fig. 4B-D), indicating enhanced inhibitory effects of dephosphorylated PLN and diminished Serca2a activity. The effector pump, Serca2a, exhibited 29% reduction in AF versus SR that did not reach statistical significance (n = 5; $P = 0.08$; Fig. 4E).

Ca$^{2+}$ release from the sarcoplasmic reticulum is mediated through RyR2 channels. During AF with reduced LVEF in pigs, phosphorylation of RyR2 by PKA at Ser2808 was significantly reduced by 62% (n = 5; $P = 0.040$), whereas total RyR2 protein (n = 5; $P = 0.50$) and CaMKII$\delta$
phosphorylation at Ser2814 (n = 5; P = 0.82) was not different between AF and SR animal groups (Fig. 5A-D).

Fig 3. Expression of L-type Ca^{2+} channels (LTCC) and Na^{+}-Ca^{2+} exchanger (NCX) 1 in AF animals and in SR controls. a, b Regulatory LTCC α_{2} subunit was significantly downregulated in AF animals, whereas the pore forming α_{1C} subunit was not affected. c AF lead to significant upregulation of the NCX1 transporter. Representative Western blots and mean (± SEM) optical density data normalized to GAPDH are displayed (n = 5 animals per group). *P < 0.05; **P < 0.001.
**Fig 4.** Alterations of sarcoplasmic reticulum Ca\(^{2+}\)-ATPase (Serca) 2a and its regulator phospholamban (PLN) during AF. Total PLN (a) and PLN phosphorylated by CaMKII (Thr17; b) or PKA (Ser16; c) was downregulated in AF animals. 

**d** Phosphorylation levels relative to total PLN. 

**e** Serca2a protein analysis revealed a trend towards reduced protein expression associated with AF. Mean ± SEM optical density data normalized to GAPDH obtained from n = 5 Western blots per group are displayed. *P < 0.05; **P < 0.01.

doi:10.1371/journal.pone.0116395.g004

**Fig 5.** Analysis of ryanodine receptor (RyR) and phosphorylated ryanodine receptor (p-RyR) levels in SR and AF pigs. 

**a** Total RyR protein did not differ between animal groups. 

**b, c** PKA-phosphorylated RyR at Ser2808 was reduced, while CaMKII-phosphorylated RyR at Ser2814 was not affected by AF. 

**d** Relative p-RyRSer2808 but not p-RyRSer2814 content was diminished in atrial tissue obtained from n = 5 animals per group. Original Western blots and mean normalized optical density data are provided (*P < 0.05).

doi:10.1371/journal.pone.0116395.g005
Discussion

Remodeling of Ca\textsuperscript{2+} signaling in AF complicated by tachymyopathy: implications for cellular arrhythmogenesis

This work reveals distinct alterations of Ca\textsuperscript{2+} signaling in a large animal model of AF and functional alterations of the LV. Here, AF and mild HF resulted in prolongation of AERP. This unexpected finding is attributed to reduced K\textsuperscript+ channel expression \cite{18,19} and highlights the distinction of this sub-entity of AF. Prolongation of atrial refractoriness in isolation will enhance LTCC-mediated depolarizing Ca\textsuperscript{2+} influx during the plateau phase of each action potential, leading to early afterdepolarizations (EADs). However, autoprotective LTCC downregulation (Fig. 6) directly limits Ca\textsuperscript{2+} entry to reduce toxic cytosolic Ca\textsuperscript{2+} overload, excessive ERP prolongation, and EAD generation. AF animals with diminished cardiac function exhibited decreased Serca2a expression (Fig. 6). In addition, dephosphorylated PLN that inhibits Serca2a function was associated with reduced expression of CaMKII\textsubscript{δ} and phosphorylated regulatory RII\textsubscript{α} PKA subunits after 7 days of AF. Functional cellular consequences of Ca\textsuperscript{2+} handling alterations and their impact on atrial arrhythmogenesis require further investigation.

Comparison with previous studies in animal models and humans

Reduction of LVEF and enlarged left atrial diameters are consistent with tachymyopathy in predisposed human AF subjects. In most studies of human chronic (but not paroxysmal) AF \cite{8,9} and in AF models that do not develop HF \cite{5,11,20–23} action potential shortening has been reported. Thus, prolongation of atrial refractoriness observed in AF / HF pigs is a remarkable finding that may represent a hallmark of AF in combination with HF and reduced ejection fraction \cite{24–27}. In humans, clinically and mechanistically relevant overlap between sinoatrial node (SAN) dysfunction and atrial fibrillation has been observed \cite{28,29}. In dogs, AF induced by long term atrial burst pacing resulted in SAN dysfunction with prolonged SNRT \cite{30,31}. We noted a trend towards prolonged SNRT in pigs after short term follow-up that may indicate AF-related impairment of SAN function in line with previous reports.

![Fig 6. Remodeling of Ca\textsuperscript{2+} handling proteins during atrial fibrillation and heart failure](image_url)

Changes in protein expression are indicated by arrows (orange color). Solid black arrows indicate transport directions of Ca\textsuperscript{2+} or Na\textsuperscript{+} ions, respectively. Decreased levels of Ca\textsuperscript{2+}-calmodulin-dependent protein kinase (CaMK) II\textsubscript{δ} and protein kinase A (PKA) causes hypophosphorylation of phospholamban (PLN) and ryanodine receptor (RyR) 2, leading to reduced Ca\textsuperscript{2+} uptake into the sarcoplasmic reticulum through sarcoplasmic reticulum Ca\textsuperscript{2+}-ATPase (Serca) 2a. Increased intracellular Ca\textsuperscript{2+} levels and upregulation of Na\textsuperscript{+}-Ca\textsuperscript{2+} exchanger (NCX) 1 expression enhance electrogentic Na\textsuperscript{+}-Ca\textsuperscript{2+} exchange. This mechanism is attenuated by reduced L-type calcium channel (LTCC) expression that limits systolic Ca\textsuperscript{2+} influx.

doi:10.1371/journal.pone.0116395.g006
At the molecular level, proarrhythmic remodeling of Ca\(^{2+}\) handling was complex and exhibited specific characteristics that differed from findings obtained during AF or HF in isolation, respectively. Previous studies revealed that in the absence of relevant ventricular dysfunction, AF is primarily characterized by elevated NCX1 levels and LTCC downregulation \([7,27,32]\). Active PKA and CamKII are upregulated, leading to RyR2 phosphorylation at Ser2808 (PKA) and Ser2814 (CaMKII; observed in cAF but not pAF) that causes diastolic Ca\(^{2+}\) leak, DADs, and ectopic activity \([8,9,23,27,32]\). In addition, increased activity of regulatory protein kinases accounts for PLN phosphorylation. Phosphorylation relieves PLN inhibition of Serca2a and results in increased sarcoplasmic reticulum Ca\(^{2+}\) load that further supports DAD generation \([23]\). Serca2a protein levels are reduced in isolated AF \([32]\). Of note, complex and differing data on Ca\(^{2+}\) remodeling suggested that precise mechanisms likely differ between patient subpopulations \([33]\). Similar to AF in the absence of reduced LV function, the combined phenotype of AF and HF studied here displayed increased NCX1 and decreased LTCC and Serca2a levels, respectively (Fig. 6). In the present work, however, atrial remodeling of AF / HF animals was characterized by downregulation of phosphorylated PKA RII\(\alpha\) and CaMKII with subsequent hypophosphorylation of PLN and RyR2 (Fig. 6) in contrast to alterations in AF without relevant structural impairment of the heart.

In animal models or patients with HF, the downregulation of Serca2a and LTCC as well as NCX1 upregulation are consistent findings in atrial myocytes \([6,7,32]\), similar to AF and AF / HF subjects. In addition, previous studies of atrial remodeling in HF revealed characteristic downregulation and hypophosphorylation of RyR2 \([27,32]\). The latter observation is shared by AF / HF pigs and distinguishes this disease sub-entity from “common” AF without reduced LV function. The primary mechanism of atrial arrhythmogenesis in HF appears to be increased CaMKII function and CaMKII-dependent PLN hyperphosphorylation that attenuate Serca2a inhibition, leading to Ca\(^{2+}\) overload of the sarcoplasmatic reticulum and DADs \([27,32,34]\). By contrast, the absence of these CaMKII-dependent changes appears to be unique to AF / HF hearts and has not been reported previously. Whether CaMKII downregulation and reduced phosphorylation of downstream proteins are specific characteristics of the porcine AF model or reflections of a general mechanism in an underexplored AF / HF sub-entity of the arrhythmia remains to be determined.

**Therapeutic implications**

Distinct remodeling of Ca\(^{2+}\) cycling in AF / HF subjects requires specific therapeutic approaches. Class III antiarrhythmic drugs that further prolong action potential duration and AERP may be less effective in these cases. Decreased Serca2a expression and function provide potential targets for antiarrhythmic therapy. Therapeutic stimulation of Serca2a could reduce cytosolic Ca\(^{2+}\) levels and attenuate arrhythmogenic NCX1-mediated Ca\(^{2+}\) elimination. This would, however, be associated with sarcoplasmic reticulum Ca\(^{2+}\) overload, increasing the risk of diastolic Ca\(^{2+}\) leak and DADs. In addition, inhibition of L-type Ca\(^{2+}\) channels that are downregulated in AF / HF animals may protect from EAD generation and ERP prolongation, but negative inotropic effects render this concept unsuitable in HF patients. Finally, attenuation of AERP prolongation without negative effects on intracellular Ca\(^{2+}\) homeostasis could be achieved by specific activation of atrial-selective K\(^{+}\) channels (e.g. K\(_{2P}\) channels; \([18,19]\)).

**Potential limitations and future directions**

Experimental large animal models do not show spontaneous AF occurrence that is observed in AF patients. Nonetheless, the unique porcine model used in this work is comparable to the clinical scenario of AF and left ventricular dysfunction due to rapid ventricular rate response.
Thus, we suggest that the pig is a valid model system to analyse atrial remodeling in the context of AF complicated by HF. Functional analyses were limited to in vivo studies among AF animals, precluding experimental confirmation of proposed arrhythmogenic mechanisms at the cellular level. The 7 day follow-up period in the present study reflects short-term remodeling processes during AF in subjects with slightly diminished ventricular function. For further evaluation of atrial Ca²⁺ cycling alterations, long term investigations of AF pigs with more advanced HF should be performed. Additional studies are required in AF patients with concomitant HF to further validate our data, as remodeling in experimental atrial tachypacing-induced AF with acute HF may differ from clinical AF / HF findings. This is particularly important because time-dependent effects during AF and chronic heart disease cannot be assessed during short-term studies in pigs. Finally, atrial-selective K<sub>2P</sub> channel activation requires in vitro and in vivo evaluation as antiarrhythmic concept to treat AF in combination with HF.

Conclusions

We present new insights into atrial remodeling of Ca²⁺ signaling in AF complicated by reduced ventricular function. Complex remodeling of proteins involved in Ca²⁺ cycling in AF / HF animals yields a distinct expression and phosphorylation pattern that cannot be explained by the summation of changes observed in isolated HF or AF. The data provide an explanation why the arrhythmia is particularly difficult to treat in a sub-entity of AF patients with concomitant HF, serving as a starting point for more personalized AF treatment.

Acknowledgments

We thank Jennifer Gütermann, Kai Sona, and Nadine Weiberg for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: PL PAS HAK DT. Performed the experiments: PL FW KG DT. Analyzed the data: PL FW KG PAS HAK DT. Wrote the paper: PL FW KG PAS HAK DT.

References

1. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, et al. (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107: 2920–2925. doi:10.1161/01.CIR.0000072767.89944.6E PMID: 12771006
2. Kato T, Yamashita T, Sagara K, Inuma H, Fu LT (2004) Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J 68: 568–572. doi:10.1253/circj.68.568 PMID: 15170094
3. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, et al. (2005) Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 149: 489–496. doi:10.1016/j.ahj.2004.09.053 PMID: 15864238
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 285: 2370–2375. doi:10.1001/jama.285.18.2370
5. Allessie M, Ausma J, Schotten U (2002) Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54: 230–246. doi:10.1016/S0008-6363(02)00258-4 PMID: 12062329
6. Nattel S, Shiroshita-Takeshita A, Brundel BJ, Rivard L (2005) Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 48: 9–28. doi:10.1016/j.pcad.2005.06.002 PMID: 16194689
7. Nattel S, Maguy A, Le Bouter S, Yeh YH (2007) Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87: 425–456. doi:10.1152/physrev.00014.2006 PMID: 17429037
8. Voigt N, Li N, Wang Q, Wang W, Trafford AW, et al. (2012) Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 125: 2059–2070. doi: 10.1161/CIRCULATIONAHA.111.067306 PMID: 22456474

9. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, et al. (2014) Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 129: 145–156. doi: 10.1161/CIRCULATIONAHA.113.006641 PMID: 24249718

10. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, et al. (2000) Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101: 2631–2638. doi: 10.1016/01.01.CIR.101.22.2631 PMID: 10840016

11. Cha TJ, Ehrlich JR, Zhang L, Nattel S (2004) Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. Circulation 110: 1520–1526. doi: 10.1016/01.01.CIR.0000142052.03565.87 PMID: 15381657

12. Bauer A, McDonald AD, Donahue JK (2004) Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 61: 764–770. doi: 10.1016/j.cardiores.2003.12.013 PMID: 14985073

13. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, et al. (2011) Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92: 218–225. doi: 10.1093/cvr/cvr209 PMID: 21799069

14. Lugenbiel P, Thomas D, Kelemen K, Trappe K, Bikou O, Schweizer PA, Voss F, Becker R, Katus HA, Bauer A (2012) Genetic suppression of Galpha(s) protein provides rate control in atrial fibrillation. Basic Res Cardiol 107: 265. doi: 10.1007/s00395-012-0265-5 PMID: 22457123

15. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, et al. (2012) Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 9: 265–272. doi: 10.1016/j.hrthm.2011.09.008 PMID: 21907712

16. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, et al. (2013) Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J 34: 147–157. doi: 10.1093/eurheartj/ehs269 PMID: 21785105

17. Lugenbiel P, Bauer A, Kelemen K, Schweizer PA, Becker R, et al. (2012) Biological heart rate reduction through genetic suppression of Gaip alpha(s) protein in the sinoatrial node. J Am Heart Assoc 1: jah3–e000372. doi: 10.1161/JAHA.111.000372 PMID: 23130125

18. Schmidt C, Wiedmann F, Langer C, Tristram F, Anand P, et al. (2014) Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. Heart Rhythm 11: 1798–1805. doi: 10.1016/j.hrthm.2014.06.020 PMID: 24952150

19. Schmiedebergs Arch Pharmacol 381: 195–207. doi: 10.1161/CIRCEP.109.933036 PMID: 20660541

20. Walili R, Yeh Yh, Qi XY, Greiser M, Chartier D, et al. (2008) Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 1: 93–102. doi: 10.1016/j.hrthm.2011.09.008 PMID: 19808399

21. Dobrev D (2010) Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch Pharmacol 381: 195–206. doi: 10.1007/s00210-009-0457-1 PMID: 19784635
28. Duhme N, Schweizer PA, Thomas D, Becker R, Schröter J, et al. (2013) Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart J 34: 2768–2775. doi: 10.1093/eurheartj/ehs391 PMID: 23178648

29. Schweizer PA, Schröter J, Greiner S, Haas J, Yampolsky P, et al. (2014) The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel. J Am Coll Cardiol 64: 757–767. doi: 10.1016/j.jacc.2014.06.1155 PMID: 25145518

30. Elvan A, Wylie K, Zipes DP (1996) Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 94: 2953–2960. doi: 10.1161/01.CIR.94.11.2953 PMID: 8941126

31. Joung B, Lin SF, Chen Z, Antoun PS, Maruyama M, et al. (2010) Mechanisms of sinoatrial node dysfunction in a canine model of pacing-induced atrial fibrillation. Heart Rhythm 7: 88–95. doi: 10.1016/j.hrthm.2009.09.018 PMID: 19914141

32. Heijman J, Voigt N, Nattel S, Dobrev D (2014) Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 114: 1483–1499. doi: 10.1161/CIRCRESAHA.114.302226 PMID: 24763466

33. Schotten U, Verheule S, Kirchhof P, Goette A (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91: 265–325. doi: 10.1152/physrev.00031.2009 PMID: 21248168

34. Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124: 2264–2274. doi: 10.1161/CIRCULATIONAHA.111.019893 PMID: 22083148